NASDAQ: IRWDIronwood Pharmaceuticals Inc Stock
$3.65+0.02 (+0.55%)
Updated Jun 12, 2026
IRWD Price
$3.65
Fair Value Price
N/A
Market Cap
$600.84M
52 Week Low
$0.62
52 Week High
$5.78
P/E
5.7x
P/B
-2.77x
P/S
1.59x
PEG
0.18x
Dividend Yield
N/A
Revenue
$361.51M
Earnings
$102.18M
Gross Margin
100%
Operating Margin
56.79%
Profit Margin
28.3%
Debt to Equity
-3
Operating Cash Flow
$112M
Beta
0.76
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
IRWD Overview
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRWD's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
IRWD
Ranked#5 of 51
Ranked#5 of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.48 | A | |
| $34.64 | A | |
| $16.48 | A |
Be the first to know about important IRWD news, forecast changes, insider trades & much more!
IRWD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRWD ($3.65) is trading below its intrinsic value of $10.15, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IRWD is good value based on its earnings relative to its share price (5.7x), compared to the US market average (14.15x)
P/E vs Market Valuation
IRWD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more IRWD due diligence checks available for Premium users.
Valuation
IRWD fair value
Fair Value of IRWD stock based on Discounted Cash Flow (DCF)
Price
$3.65
Fair Value
$11.59
Undervalued by
68.50%
IRWD ($3.65) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.7x
Industry
-5.05x
Market
14.15x
IRWD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
IRWD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
IRWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.77x
Industry
1.57x
IRWD price to earnings growth (PEG)
For valuing profitable companies with growth potential
IRWD is good value based... subscribe to Premium to read more.
PEG Value Valuation
IRWD's financial health
Profit margin
Revenue
$106.5M
Net Income
$40.8M
Profit Margin
38.3%
IRWD's Earnings (EBIT) of $205.29M... subscribe to Premium to read more.
Interest Coverage Financials
IRWD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$434.6M
Liabilities
$651.7M
Debt to equity
-3
IRWD's short-term assets ($332.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRWD's long-term liabilities ($415.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$5.1M
Investing
$0.0
Financing
$0.0
IRWD's operating cash flow ($112.21M)... subscribe to Premium to read more.
Debt Coverage Financials
IRWD vs Pharmaceutical Stocks
Ironwood Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.